186 results on '"Chen, Naijun"'
Search Results
2. CTRP13 alleviates palmitic acid-induced inflammation, oxidative stress, apoptosis and endothelial cell dysfunction in HUVECs
3. Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network
4. Janus Kinase Inhibitor Therapy and Risk of Age-Related Macular Degeneration in Autoimmune Disease.
5. Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach
6. Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States
7. Letter to the Editor: Re-Revisiting the Association Between Inflammatory Bowel Disease and Parkinson’s Disease
8. The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus: A meta-analysis
9. Economic Burden Of Fatigue In Inflammatory Bowel Disease
10. Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States
11. Reliability and Validity of the Work Instability Scale for Rheumatoid Arthritis
12. Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation
13. Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
14. Adalimumab Induces Deep Remission in Patients With Crohn's Disease
15. Development and initial validation of the HS‐IGA : a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials*
16. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial
17. Zero-Inflated Ordinal Mixed-Effects Models
18. Comparative Risks of Leukopenia, Pancytopenia, Infections, Cardiovascular Events, and Malignancy with First Line Conventional Synthetic Disease-Modifying Antirheumatic Drugs (CsDMARDs) in Rheumatoid Arthritis: An International Multinational Network Cohort Study
19. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis
20. Interrelationship Between 2019-nCov Receptor DPP4 and Diabetes Mellitus Targets Based on Protein Interaction Network
21. 103 HIGHER RESOURCE UTILIZATION AND ECONOMIC BURDEN ASSOCIATED WITH FATIGUE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
22. Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
23. Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States
24. S0896 Descriptive Assessment of Quality of Care Indicators Among Patients With Crohn’s Disease and Ulcerative Colitis in the United States
25. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
26. The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus: A protocol for systematic review and meta-analysis.
27. Anti–Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease
28. P-119: Low Cost Perovskite Quantum Dots Film Based Wide Color Gamut Backlight Unit for LCD TVs
29. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA
30. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials
31. Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada
32. Effect of Adalimumab dose Escalation on Clinical, Health-Related Quality of Life, Treatment Satisfaction and Work Productivity Outcomes Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada
33. C NMR study of halogen bonding of halorenes: measurements of solvent effects and theoritical analysis
34. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate
35. Mo1097 Adalimumab Improves Treatment Satisfaction With Medication and Work Productivity Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From INSPIRADA
36. Mo1090 The Costs of Care for Patients With Ulcerative Colitis: Effect of Adalimumab on Health Care Resources Utilisation in Clinical Practice From INSPIRADA
37. Mo1096 Effect of Adalimumab on Clinical Outcomes and Health-Related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From INSPIRADA
38. Mo1864 Current Trends in the Quality of Care of Inflammatory Bowel Disease in the United States
39. Tu1933 Fecal Calprotectin Improves the Predictive Power of 3 Practical Indices for Mucosal Healing Among Patients With Crohn's Disease: Results From PREDICT
40. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis
41. Adalimumab Therapy Reduces Hospitalization Rates in Patients With Moderate Ulcerative Colitis
42. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS)
43. Mo1660 - Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada
44. Mo1659 - Effect of Adalimumab dose Escalation on Clinical, Health-Related Quality of Life, Treatment Satisfaction and Work Productivity Outcomes Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada
45. Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study.
46. 60. Work Related Outcomes in Early Rheumatoid Arthritis Patients with Elevated Risk of Employment Loss: Results from Two Randomized Clinical Trials (Optima and Prowd) on the Effect of Adalimumab and Methotrexate Combination Therapy Versus Methotrexate Monotherapy Over 6 Months of Treatment
47. Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
48. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
49. Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study
50. Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.